Vice President, Regulatory Affairs
Haleon
Erin Oliver is currently Vice President and Regulatory Lead for Rx to OTC Switch for Haleon (formerly GlaxoSmithKline Consumer Healthcare). With 20+ years in the pharmaceutical industry, she has broad experience in the development and regulation of Rx and OTC drugs, medical devices, dietary supplements and cosmetics.
Erin’s experience in both global and US leadership roles spans multiple areas of focus (CMC, clinical, advertising and promotion, business development, regulatory strategy) and the entirety of the regulatory lifecycle. She’s helped teams progress early development programs; navigate the regulatory filing, review and Advisory Committee processes; and effectively manage post-approval lifecycle activities. Most recently, Erin has focused on the area of Rx to OTC switch, expanding the spectrum of nonprescription medicines available to help consumers to manage their health and wellness. She has written and presented at various symposia on topics relevant to consumer healthcare including Rx to OTC switch, OTC labeling development, and the role of technology in promoting self-care.
Erin holds a B.S. degree in Biology and M.S. degree in Pharmaceutics from Rutgers University as well as an MBA from Cornell University. Erin is a certified regulatory professional and a fellow of the Regulatory Affairs Professional Society. She’s served as adjunct faculty at Fairleigh Dickinson University School of Pharmacy teaching in the area of regulatory affairs and compliance.
Disclosure information not submitted.
Wednesday, October 4, 2023
4:45 PM – 5:45 PM EDT